Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Mar;21(3):771-788.e10.
doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22.

I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

Laurent Peyrin-Biroulet  1 , Jean-François Rahier  2 , Julien Kirchgesner  3 , Vered Abitbol  4 , Sebastian Shaji  5 , Alessandro Armuzzi  6 , Konstantinos Karmiris  7 , Javier P Gisbert  8 , Peter Bossuyt  9 , Ulf Helwig  10 , Johan Burisch  11 , Henit Yanai  12 , Glen A Doherty  13 , Fernando Magro  14 , Tamás Molnar  15 , Mark Löwenberg  16 , Jonas Halfvarson  17 , Edyta Zagorowicz  18 , Hélène Rousseau  19 , Cédric Baumann  19 , Filip Baert  20 , Laurent Beaugerie  3 ; I-CARE Collaborator Group
Collaborators, Affiliations
Free article
Observational Study

I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

Laurent Peyrin-Biroulet et al. Clin Gastroenterol Hepatol. 2023 Mar.
Free article

Abstract

Background and aims: There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care. The primary objective of I-CARE (IBD Cancer and serious infections in Europe) was to assess prospectively safety concerns in IBD, with specific focus on the risk of cancer/lymphoma and serious infections in patients treated with anti-tumor necrosis factor and other biologic monotherapy as well as in combination with immunomodulators.

Methods: I-CARE was designed as a European prospective longitudinal observational multicenter cohort study to include patients with a diagnosis of Crohn's disease, ulcerative colitis, or IBD unclassified established at least 3 months prior to enrollment.

Results: A total of 10,206 patients were enrolled between March 2016 and April 2019, including 6169 (60.4%) patients with Crohn's disease, 3853 (37.8%) with ulcerative colitis, and 184 (1.8%) with a diagnosis of IBD unclassified. Thirty-two percent of patients were receiving azathioprine/thiopurines, 4.6% 6-mercaptopurine, and 3.2% methotrexate at study entry. At inclusion, 47.3% of patients were treated with an anti-tumor necrosis factor agent, 8.8% with vedolizumab, and 3.4% with ustekinumab. Roughly one-quarter of patients (26.8%) underwent prior IBD-related surgery. Sixty-six percent of patients had been previously treated with systemic steroids. Three percent of patients had a medical history of cancer prior to inclusion and 1.1% had a history of colonic, esophageal, or uterine cervix high-grade dysplasia.

Conclusions: I-CARE is an ongoing investigator-initiated observational European prospective cohort study that will provide unique information on the long-term benefits and risks of biological therapies in IBD patients. (EudraCT, Number: 2014-004728-23; ClinicalTrials.gov, Number: NCT02377258).

Keywords: Biologics; Cancer; Efficacy; I-CARE; Inflammatory Bowel Disease; Lymphoma; Safety.

PubMed Disclaimer

Publication types

Associated data